"Both stocks are cheap by historical healthcare standards, but Cigna is cheaper on the metrics that matter most. CVS trades at roughly 11.3x trailing adjusted earnings against approximately 9.4x for Cigna. On a forward basis, Cigna's 2026 adjusted EPS guidance of at least $30.25 puts it at roughly 9.3x against CVS's forward multiple near 10.7x using its 2026 adjusted EPS midpoint of $7.10."
"What makes Cigna's lower multiple more compelling is that it comes alongside far stronger earnings quality. Net income grew 73.47% year-over-year in FY2025 to $5.957 billion, while CVS net income fell 62.55% to $1.728 billion, weighed down by a $5.7 billion goodwill impairment and roughly $1.2 billion in legacy litigation charges."
"The stock pays $0.665 per quarter, or $2.66 annualized, and has raised its dividend from $0.55 per quarter in 2022 to the current rate. At the current price of $76.07, that annualized payout translates to a yield approaching 3.5%, a meaningful income stream for retirees."
CVS Health and Cigna Group represent different investment philosophies for retirement portfolios. Cigna trades at lower valuation multiples (9.3x-9.4x versus CVS's 10.7x-11.3x) with significantly stronger earnings quality, evidenced by 73.47% year-over-year net income growth compared to CVS's 62.55% decline caused by goodwill impairment and litigation charges. CVS compensates with a higher dividend yield of approximately 3.5% annualized ($2.66 per share) versus Cigna's 2.3%, supported by a massive $402 billion revenue base and substantial operating cash flow. Cigna demonstrates consistent earnings beat performance across all 2025 quarters, suggesting reliable growth trajectory and capital discipline.
#healthcare-stock-comparison #dividend-yield-and-income #valuation-analysis #earnings-quality #retirement-investment
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]